title: Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease.
authors.forename: Livia
authors.initials: L
authors.lastname: Biancone
authors.forename: Claudio
authors.initials: C
authors.lastname: Tosti
authors.forename: Francesca
authors.initials: F
authors.lastname: De Nigris
authors.forename: Massimo
authors.initials: M
authors.lastname: Fantini
authors.forename: Francesco
authors.initials: F
authors.lastname: Pallone
mesh_terms: D000328:Adult; D000368:Aged; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000517:prevention & control*; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007783:Lactones / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008565:Membrane Proteins; D008875:Middle Aged; D011446:Prospective Studies; D011451:Prostaglandin-Endoperoxide Synthases; D012008:Recurrence; D013450:Sulfones
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases